Current stock page

Financial Data

MBX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MBXMBX Biosciences, Inc. Common Stock

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$55.94+$1.43 (+2.62%)

Latest quote

  • Momentum
    71
  • Value
    —
  • Quality
    74
  • Risk resilience
    50
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0-$64K-$60K-$100K$0$0$0
Operating Income-$66.34M-$40.93M-$27.27M-$25.8M-$23.93M-$21.81M-$26.53M-$18.61M
Net Income-$62.42M-$37.1M-$23.52M-$22.06M-$21.62M-$19.41M-$23.88M-$15.59M
EPS-$1.29-$0.78-$0.5-$0.49-$0.63-$0.58-$0.71-$0.47
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$34.88M-$22.62M-$20.21M-$18.3M-$21.54M-$17.43M-$22.68M-$16.04M
Capital Expenditure-$1.19M-$901K-$437K-$793K-$399K-$707K-$30K-$92K
Free Cash Flow-$36.07M-$23.52M-$20.65M-$19.09M-$21.94M-$18.14M-$22.71M-$16.13M
Net Cash Provided By Operating Activities-$34.88M-$22.62M-$20.21M-$18.3M-$21.54M-$17.43M-$22.68M-$16.04M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$500.62M$435.91M$452.7M$385.14M$400.08M$231.52M$245.93M$268.54M
Total Debt$3.29M$3.34M$555K$596K$623K$650K$130K$171K
Cash And Cash Equivalents$161.69M$54.12M$45.21M$75.29M$223.13M$39.78M$29.9M$49.35M
Total Liabilities$27.67M$26.37M$14.95M$15.92M$12.54M$12.28M$10.5M$11.09M
Total Stockholders Equity$472.95M$409.54M$437.76M$369.22M$387.54M$219.24M$235.42M$257.44M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.557.823.692.762.181.7——
P/S ratio————————
Debt To Equity0.010.01000000
Free Cash Flow Yield-3.78%-2.66%-4.94%-8.02%-9.33%-19.26%——
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.557.823.692.762.181.7——
P/S ratio————————
Return On Equity-30.68%-25.47%-19.78%-23.56%-20.77%-35.13%-31.21%-24.05%
Debt To Equity0.010.01000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-18.28x
Pb5.74x
EPS Growth Yoy-104.76%
Gross Margin0.00%
Operating Margin0.00%
ROE-34.35%
ROIC-33.67%
Debt To Equity0.01
FCF Yield-3.58%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$55.94
Volume855,453
RSI (14)53.28
MACD0.07
MACD signal-0.56
MACD histogram0.63
ADX (14)13.7
SMA (50)$55.78
SMA (200)$46.32
ATR (14)$3.80
Historical volatility (annualized)68.24%
Volume (20-day average)537,599

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score50/100
Beta1.26
Annual volatility77.34%
Max Drawdown-37.60%
Sharpe Ratio1.42
VaR (95%, 1-day)-7.10%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MBX Financial Data FAQ

What is MBX Biosciences, Inc. Common Stock's revenue?

MBX Biosciences, Inc. Common Stock's revenue is one of the core financial data points for MBX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is MBX Biosciences, Inc. Common Stock's revenue growing?

Revenue growth shows whether MBX Biosciences, Inc. Common Stock is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MBX's EPS?

MBX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is MBX Biosciences, Inc. Common Stock's net income?

MBX Biosciences, Inc. Common Stock's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does MBX Biosciences, Inc. Common Stock generate?

Free cash flow shows how much cash MBX Biosciences, Inc. Common Stock generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does MBX Biosciences, Inc. Common Stock have?

Cash and debt help frame MBX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.